

JFW

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-499US

In Re Application Of: **SINGH et al.**

JUN 22 2007

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/598,546	5/4/2006	Unknown	26815	Unknown	7158

**Title: PROCESSES FOR THE PREPARATION OF SOLID DOSAGE FORMS OF AMORPHOUS
VALGANCICLOVIR HYDROCHLORIDE**

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
 (Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-499US

In Re Application of: **STANGH et al.**

JUN 22 2007

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/598,546	9/4/2006	Unknown	26815	Unknown	7158

Title: PROCESSES FOR THE PREPARATION OF SOLID DOSAGE FORMS OF AMORPHOUS VALGANCICLOVIR HYDROCHLORIDE

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of _____ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below.
 - Charge the amount of _____
 - Credit any overpayment.
 - Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

 (Date)

 Signature

 Typed or Printed Name of Person Signing Certificate

*This certificate may only be used if paying by deposit account.

George E. Heibel
 Signature

George E. Heibel, Esq.
 Reg. No. 42,648

CUSTOMER NO. 26,815

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

 June 19, 2007

Christine Kennedy-Renner
 Signature
 Signature of Person Mailing Correspondence

Christine Kennedy-Renner

 Typed or Printed Name of Person Mailing Certificate

Dated: **June 19, 2007**

CC:

INFORMATION DISCLOSURE CITATION <i>1498</i> JUN 22 2007	Docket No.: RLL-499US	Serial No.: 10/598,546
	Applicants: SINGH et al.	
	Filed: 9/4/2006	Group:

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	B1	IN 1053/Del/2003	8/28/2003	India			
	B2	WO 2004/010998	2/5/2004	PCT	A61K	31/428	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	